Amorphous solid dispersions (ASDs) are often metastable against crystallization of the
active pharmaceutical ingredient (API) and thus might undergo unwanted changes during …

Amorphous solid dispersions (ASDs) of a poorly water-soluble active pharmaceutical
ingredient (API) in a polymer matrix can enhance the water solubility and therefore generally …

The molecular integration of poorly water soluble active pharmaceutical ingredients (APIs) in
a suitable polymeric matrix is a possible approach to enhance the dissolution behavior and …

In formulation development, amorphous solid dispersions (ASD) are considered to improve
the bioavailability of poorly water-soluble active pharmaceutical ingredients (APIs) …

Amorphous solid dispersions (ASDs) with solubility advantage are suffering from the
recrystallization risk and subsequent reduced dissolution triggered by high hygroscopicity of …

Understanding the long-term stability of amorphous solid dispersions (ASDs) is important for
their successful approval for market. ASD stability does not only depend on the interplay …

The preparation of amorphous solid dispersions (ASDs) is a well-established strategy for
formulating active pharmaceutical ingredients by embedding them in excipients, usually …

Understanding and prevention of unwanted changes of a pharmaceutical formulation during
the production process is part of the critical requirements for the successful approval of a …

The most common drawback of the existing and novel drug molecules is their low
bioavailability because of their low solubility. One of the most important approaches to …

Amorphous solid dispersions (ASDs) are often used for formulating poorly water-soluble
active pharmaceutical ingredients (APIs). In an ASD, the amorphous API is embedded in a …